Buyers must provide specific active pharmaceutical ingredients (APIs), dosage strength, formulation type (e.g., gel, patch, tablet), packaging specifications, order volume, and destination market regulatory requirements.
Category market report
Orthopedic Drugs
Total suppliers
6,829+
Total Chinese suppliers export
$9.2B+
Recommended
High-quality suppliers related to Orthopedic Drugs.
Suppliers
Find more suppliers who may be worth contacting.
Top suppliers
Suppliers in this category.
- Transactions
1,897
2018-012022-032026-08Transaction trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 4
- 2018-02: 2
- 2018-03: 3
- 2018-04: 4
- 2018-05: 3
- 2018-06: 10
- 2018-07: 5
- 2018-09: 10
- 2018-10: 2
- 2018-11: 1
- 2018-12: 1
- 2019-01: 32
- 2019-02: 19
- 2019-03: 17
- 2019-04: 13
- 2019-05: 19
- 2019-06: 16
- 2019-07: 9
- 2019-08: 5
- 2019-09: 4
- 2019-10: 7
- 2019-11: 13
- 2019-12: 15
- 2020-01: 24
- 2020-02: 1
- 2020-03: 18
- 2020-04: 30
- 2020-05: 27
- 2020-06: 14
- 2020-07: 13
- 2020-08: 38
- 2020-09: 4
- 2020-10: 21
- 2020-11: 28
- 2020-12: 16
- 2021-01: 9
- 2021-02: 42
- 2021-03: 23
- 2021-04: 20
- 2021-05: 44
- 2021-06: 23
- 2021-07: 19
- 2021-08: 33
- 2021-09: 15
- 2021-10: 46
- 2021-11: 27
- 2021-12: 22
- 2022-01: 43
- 2022-02: 9
- 2022-03: 22
- 2022-04: 30
- 2022-05: 24
- 2022-06: 26
- 2022-07: 19
- 2022-08: 18
- 2022-09: 19
- 2022-10: 34
- 2022-11: 12
- 2022-12: 37
- 2023-01: 13
- 2023-02: 19
- 2023-03: 51
- 2023-04: 22
- 2023-05: 12
- 2023-06: 26
- 2023-07: 23
- 2023-08: 17
- 2023-09: 45
- 2023-10: 10
- 2023-11: 32
- 2023-12: 15
- 2024-02: 28
- 2024-03: 12
- 2024-05: 31
- 2024-06: 18
- 2024-07: 16
- 2024-08: 6
- 2024-09: 15
- 2024-10: 16
- 2024-11: 11
- 2024-12: 14
- 2025-01: 21
- 2025-02: 14
- 2025-03: 19
- 2025-04: 13
- 2025-05: 9
- 2025-06: 11
- 2025-07: 20
- 2025-08: 17
- 2025-09: 13
- 2025-10: 7
- 2025-11: 13
- 2025-12: 16
- 2026-01: 21
- 2026-03: 13
- 2026-04: 49
- 2026-05: 33
- 2026-06: 25
- 2026-07: 28
- 2026-08: 14
- Amount
4,100,621.13
2018-012022-032026-08Amount trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 19.5M
- 2018-02: 23.3K
- 2018-03: 613.5K
- 2018-04: 401K
- 2018-05: 53.6K
- 2018-06: 195.8K
- 2018-07: 174.2K
- 2018-09: 1.4M
- 2018-10: 143.4K
- 2018-11: 27.6K
- 2018-12: 23K
- 2019-01: 40.7B
- 2019-02: 2.8M
- 2019-03: 2.4M
- 2019-04: 1.7M
- 2019-05: 2.6M
- 2019-06: 3.1M
- 2019-07: 1.8M
- 2019-08: 840.4K
- 2019-09: 772.1K
- 2019-10: 2.5M
- 2019-11: 2M
- 2019-12: 1.8M
- 2020-01: 7M
- 2020-02: 9,942.19
- 2020-03: 3.1M
- 2020-04: 4.1M
- 2020-05: 4.5M
- 2020-06: 5.9M
- 2020-07: 2.1M
- 2020-08: 7.6M
- 2020-09: 281.4K
- 2020-10: 1.8M
- 2020-11: 2.3M
- 2020-12: 2.1M
- 2021-01: 927.7K
- 2021-02: 5.9M
- 2021-03: 3M
- 2021-04: 2.8M
- 2021-05: 6.3M
- 2021-06: 4.1M
- 2021-07: 2.5M
- 2021-08: 4M
- 2021-09: 3.4M
- 2021-10: 7M
- 2021-11: 3.9M
- 2021-12: 4M
- 2022-01: 8.5M
- 2022-02: 2.3M
- 2022-03: 2.2M
- 2022-04: 5.2M
- 2022-05: 2.8M
- 2022-06: 4.1M
- 2022-07: 3.3M
- 2022-08: 2.1M
- 2022-09: 2.8M
- 2022-10: 5.3M
- 2022-11: 2M
- 2022-12: 5.9M
- 2023-01: 1.2M
- 2023-02: 3.3M
- 2023-03: 6.5M
- 2023-04: 3.4M
- 2023-05: 3.1M
- 2023-06: 3.4M
- 2023-07: 2.5M
- 2023-08: 2.8M
- 2023-09: 6.7M
- 2023-10: 1.9M
- 2023-11: 5.4M
- 2023-12: 3.1M
- 2024-02: 8.1M
- 2024-03: 3.1M
- 2024-05: 5.5M
- 2024-06: 3.3M
- 2024-07: 3M
- 2024-08: 1.3M
- 2024-09: 2.5M
- 2024-10: 2.2M
- 2024-11: 2M
- 2024-12: 1.8M
- 2025-01: 4.7M
- 2025-02: 1M
- 2025-03: 2.5M
- 2025-04: 2.9M
- 2025-05: 2.5M
- 2025-06: 1.9M
- 2025-07: 3M
- 2025-08: 1.3M
- 2025-09: 2.8M
- 2025-10: 661.9K
- 2025-11: 2M
- 2025-12: 3.1M
- 2026-01: 1.9M
- 2026-03: 697.5K
- 2026-04: 3.1M
- 2026-05: 1.7M
- 2026-06: 1.3M
- 2026-07: 799.3K
- 2026-08: 117.8K
- Main export countries
- India (0.6%)
- Sri Lanka (0%)
- Namibia (0%)
- Mexico (99.3%)
- Transactions
47
2019-012020-102021-09Transaction trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 32
- 2019-11: 2
- 2020-04: 2
- 2020-05: 1
- 2020-06: 1
- 2020-10: 1
- 2021-03: 2
- 2021-04: 1
- 2021-05: 1
- 2021-07: 1
- 2021-08: 1
- 2021-09: 2
- Amount
559,462.81
2019-012020-102021-09Amount trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 5.6B
- 2019-11: 24.9K
- 2020-04: 22.1K
- 2020-05: 11.8K
- 2020-06: 12.3K
- 2020-10: 11.9K
- 2021-03: 24.6K
- 2021-04: 12.5K
- 2021-05: 12.7K
- 2021-07: 12.5K
- 2021-08: 12.5K
- 2021-09: 25.3K
- Main export countries
- Indonesia (100%)
- Transactions
2,150
2018-012022-072026-09Transaction trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 9
- 2018-02: 12
- 2018-03: 11
- 2018-04: 7
- 2018-05: 11
- 2018-06: 19
- 2018-07: 14
- 2018-08: 21
- 2018-09: 20
- 2018-10: 15
- 2018-11: 15
- 2018-12: 10
- 2019-01: 21
- 2019-02: 4
- 2019-03: 10
- 2019-04: 12
- 2019-05: 19
- 2019-06: 9
- 2019-07: 7
- 2019-08: 17
- 2019-09: 14
- 2019-10: 9
- 2019-11: 22
- 2019-12: 14
- 2020-01: 14
- 2020-02: 16
- 2020-03: 5
- 2020-05: 6
- 2020-06: 22
- 2020-08: 18
- 2020-10: 20
- 2020-11: 21
- 2020-12: 8
- 2021-02: 8
- 2021-03: 19
- 2021-04: 10
- 2021-05: 15
- 2021-06: 9
- 2021-07: 16
- 2021-08: 11
- 2021-09: 8
- 2021-10: 18
- 2021-11: 20
- 2021-12: 28
- 2022-01: 12
- 2022-02: 18
- 2022-03: 19
- 2022-05: 17
- 2022-06: 19
- 2022-07: 25
- 2022-08: 15
- 2022-09: 41
- 2022-10: 25
- 2022-11: 28
- 2022-12: 38
- 2023-01: 30
- 2023-02: 11
- 2023-03: 43
- 2023-04: 42
- 2023-05: 29
- 2023-06: 18
- 2023-07: 25
- 2023-08: 19
- 2023-09: 15
- 2023-10: 27
- 2023-11: 24
- 2023-12: 20
- 2024-01: 44
- 2024-02: 34
- 2024-03: 21
- 2024-04: 37
- 2024-05: 32
- 2024-06: 19
- 2024-07: 16
- 2024-08: 14
- 2024-09: 21
- 2024-10: 35
- 2024-11: 44
- 2024-12: 56
- 2025-01: 39
- 2025-02: 43
- 2025-03: 41
- 2025-04: 28
- 2025-05: 31
- 2025-06: 21
- 2025-07: 32
- 2025-08: 13
- 2025-09: 16
- 2025-10: 20
- 2025-11: 15
- 2025-12: 16
- 2026-01: 24
- 2026-02: 22
- 2026-03: 30
- 2026-04: 23
- 2026-05: 37
- 2026-06: 46
- 2026-07: 14
- 2026-08: 14
- 2026-09: 24
- Amount
82,855.66
2018-012022-072026-09Amount trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 3.5M
- 2018-02: 4.8M
- 2018-03: 4.8M
- 2018-04: 1.9M
- 2018-05: 2M
- 2018-06: 5.1M
- 2018-07: 2.9M
- 2018-08: 5.5M
- 2018-09: 5.5M
- 2018-10: 4.2M
- 2018-11: 7.5M
- 2018-12: 2.4M
- 2019-01: 6.4M
- 2019-02: 1.4M
- 2019-03: 5.2M
- 2019-04: 4.2M
- 2019-05: 5.2M
- 2019-06: 3M
- 2019-07: 2.3M
- 2019-08: 5M
- 2019-09: 4.6M
- 2019-10: 3.7M
- 2019-11: 6.6M
- 2019-12: 2.5M
- 2020-01: 3.7M
- 2020-02: 5.3M
- 2020-03: 1.8M
- 2020-05: 1.9M
- 2020-06: 12.1M
- 2020-08: 5.9M
- 2020-10: 10.2M
- 2020-11: 13M
- 2020-12: 4.8M
- 2021-02: 2.9M
- 2021-03: 11.4M
- 2021-04: 4.8M
- 2021-05: 6M
- 2021-06: 5.5M
- 2021-07: 8.9M
- 2021-08: 7.6M
- 2021-09: 3.1M
- 2021-10: 9.9M
- 2021-11: 11.6M
- 2021-12: 13.5M
- 2022-01: 7.1M
- 2022-02: 12.3M
- 2022-03: 9.4M
- 2022-05: 8.1M
- 2022-06: 14.3M
- 2022-07: 16.1M
- 2022-08: 6.7M
- 2022-09: 15.5M
- 2022-10: 10.7M
- 2022-11: 12.3M
- 2022-12: 36.8M
- 2023-01: 13.5M
- 2023-02: 5.4M
- 2023-03: 17.7M
- 2023-04: 21M
- 2023-05: 11M
- 2023-06: 11.2M
- 2023-07: 9.1M
- 2023-08: 8.5M
- 2023-09: 6.3M
- 2023-10: 9.8M
- 2023-11: 9.2M
- 2023-12: 7.8M
- 2024-01: 16.7M
- 2024-02: 13.6M
- 2024-03: 6.9M
- 2024-04: 11M
- 2024-05: 10.4M
- 2024-06: 7.2M
- 2024-07: 9.3M
- 2024-08: 6.6M
- 2024-09: 5.2M
- 2024-10: 11.5M
- 2024-11: 10.1M
- 2024-12: 12.5M
- 2025-01: 10.9M
- 2025-02: 9.8M
- 2025-03: 7.5M
- 2025-04: 4.7M
- 2025-05: 7.4M
- 2025-06: 4.7M
- 2025-07: 12.4M
- 2025-08: 3.5M
- 2025-09: 5.5M
- 2025-10: 5.4M
- 2025-11: 3.7M
- 2025-12: 4.2M
- 2026-01: 6.1M
- 2026-02: 6.3M
- 2026-03: 8.5M
- 2026-04: 6.3M
- 2026-05: 16.2M
- 2026-06: 13.9M
- 2026-07: 3.7M
- 2026-08: 4.2M
- 2026-09: 6.8M
- Main export countries
- United States (99.1%)
- India (0%)
- Not available (0.9%)
Intelligence
China export momentum, destination markets, and regional demand.
China export trend
China export trend
- Date 2018-07: Value 2.8B USD
- Date 2018-08: Value 2.7B USD
- Date 2018-09: Value 2.4B USD
- Date 2018-10: Value 2.5B USD
- Date 2018-11: Value 3.1B USD
- Date 2018-12: Value 3B USD
- Date 2019-01: Value 3B USD
- Date 2019-02: Value 2B USD
- Date 2019-03: Value 3.1B USD
- Date 2019-04: Value 3.3B USD
- Date 2019-05: Value 3.7B USD
- Date 2019-06: Value 2.9B USD
- Date 2019-07: Value 3.3B USD
- Date 2019-08: Value 3.2B USD
- Date 2019-09: Value 3.2B USD
- Date 2019-10: Value 3.3B USD
- Date 2019-11: Value 3.8B USD
- Date 2019-12: Value 3.7B USD
- Date 2020-01: Value 0 USD
- Date 2020-02: Value 5.5B USD
- Date 2020-03: Value 4B USD
- Date 2020-04: Value 3.8B USD
- Date 2020-05: Value 3.1B USD
- Date 2020-06: Value 0 USD
- Date 2020-07: Value 0 USD
- Date 2020-08: Value 0 USD
- Date 2020-09: Value 3.8B USD
- Date 2020-10: Value 2.8B USD
- Date 2020-11: Value 3.3B USD
- Date 2020-12: Value 3B USD
- Date 2021-01: Value 202M USD
- Date 2021-02: Value 170M USD
- Date 2021-03: Value 201M USD
- Date 2021-04: Value 224M USD
- Date 2021-05: Value 190M USD
- Date 2021-06: Value 195M USD
- Date 2021-07: Value 215M USD
- Date 2021-08: Value 188M USD
- Date 2021-09: Value 225M USD
- Date 2021-10: Value 227M USD
- Date 2021-11: Value 221M USD
- Date 2021-12: Value 246M USD
- Date 2022-01: Value 248M USD
- Date 2022-02: Value 181M USD
- Date 2022-03: Value 266M USD
- Date 2022-04: Value 221M USD
- Date 2022-05: Value 237M USD
- Date 2022-06: Value 216M USD
- Date 2022-07: Value 236M USD
- Date 2022-08: Value 231M USD
- Date 2022-09: Value 225M USD
- Date 2022-10: Value 196M USD
- Date 2022-11: Value 249M USD
- Date 2022-12: Value 214M USD
- Date 2023-01: Value 196M USD
- Date 2023-02: Value 183M USD
- Date 2023-03: Value 223M USD
- Date 2023-04: Value 208M USD
- Date 2023-05: Value 243M USD
- Date 2023-06: Value 235M USD
- Date 2023-07: Value 187M USD
- Date 2023-08: Value 224M USD
- Date 2023-09: Value 233M USD
- Date 2023-10: Value 174M USD
- Date 2023-11: Value 214M USD
- Date 2023-12: Value 240M USD
- Date 2024-01: Value 310M USD
- Date 2024-02: Value 203M USD
- Date 2024-03: Value 280M USD
- Date 2024-04: Value 254M USD
- Date 2024-05: Value 216M USD
- Date 2024-06: Value 297M USD
- Date 2024-07: Value 261M USD
- Date 2024-08: Value 277M USD
- Date 2024-09: Value 271M USD
- Date 2024-10: Value 250M USD
- Date 2024-11: Value 289M USD
- Date 2024-12: Value 349M USD
- Date 2025-01: Value 313M USD
- Date 2025-02: Value 216M USD
- Date 2025-03: Value 296M USD
- Date 2025-04: Value 291M USD
- Date 2025-05: Value 290M USD
- Date 2025-06: Value 289M USD
- Date 2025-07: Value 313M USD
- Date 2025-08: Value 290M USD
- Date 2025-09: Value 296M USD
- Date 2025-10: Value 205M USD
- Date 2025-11: Value 315M USD
- Date 2025-12: Value 317M USD
- Date 2026-01: Value 329M USD
- Date 2026-02: Value 236M USD
- Date 2026-03: Value 287M USD
- Date 2026-04: Value 305M USD
- Date 2026-05: Value 279M USD
- Date 2026-06: Value 350M USD
- Date 2026-07: Value 334M USD
Top destinations
- Germany22.3B
- United States10.8B
- France7B
- Italy6.9B
- Sweden6.9B
- United Kingdom4.8B
- Japan3.8B
- Switzerland3.3B
- Australia3.1B
- Puerto Rico2.7B
Top destinations
- Germany: 22,334,000,000 USD
- United States: 10,827,000,000 USD
- France: 6,966,000,000 USD
- Italy: 6,949,000,000 USD
- Sweden: 6,944,000,000 USD
- United Kingdom: 4,811,000,000 USD
- Japan: 3,780,000,000 USD
- Switzerland: 3,267,000,000 USD
- Australia: 3,082,000,000 USD
- Puerto Rico: 2,732,000,000 USD
Key findings
Largest import market
22.33B USD
Germany · last 8 years
Fastest demand growth
56,399.16
Montenegro · last 8 years
Highest unit price
$592.96 /kg
Puerto Rico · +2,349.55% vs avg
Turn this market into qualified conversations.
Your agent contacts, compares, and screens the suppliers that fit.
Insights
Product insights to guide your sourcing.
Product Trends
Transdermal patches with hydrogel technology and herbal extracts see growing demand for joint pain relief. Easy-to-administer liquid formulations and enteric capsules are also gaining traction in aging markets.
Industrial Cluster Analysis
Henan province excels in high-volume production of topical orthopedic patches with high cost-efficiency. Shandong leads in advanced bio-pharmaceutical formulations, offering superior API integration for strict quality buyers.
Quality Expectations
Buyers expect stable transdermal absorption and skin allergy rates below 1% for topical drugs. For oral orthopedic drugs, consistent bioavailability and rapid dissolution under standard stability tests are critical baselines.
What You Need to Know
Request batch-specific Certificates of Analysis (COA), GMP compliance certificates, and stability test reports. Buyers should also order clinical evaluation samples or third-party lab testing before bulk shipments.
Custom formulation MOQs typically start at 50,000 units, while standard catalog items require 10,000 units. Production takes 30 to 45 days, as strict microbiological incubation and quality clearance are required.
Budget for local regulatory filing and registration fees, custom formulation R&D costs, third-party laboratory verification, and potential temperature-controlled logistics for sensitive pharmaceutical shipments.
